# A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

> **NCT01731925** · PHASE2 · UNKNOWN · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 44 (actual)

## Conditions studied

- Carcinoid Tumors

## Interventions

- **DRUG:** Lanreotide
- **DRUG:** Placebo (for sunitinib)
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01731925
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01731925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01731925, "A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01731925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*